采用常规抗心衰药物联合β-受体阻滞剂治疗心力衰竭的临床价值分析
Journal: Frontier Forum of Clinical Medicine DOI: 10.12238/ffcr.v3i6.17229
Abstract
目的：剖析心力衰竭联用常规抗心衰药物和β-受体阻滞剂的作用。方法：随机均分2023年7月-2025年6月本院接诊心力衰竭病人（N=82）。试验组用常规抗心衰竭药物和β-受体阻滞剂，对照组用常规抗心衰竭药物。对比不良反应等指标。结果：关于LVEDD和LVEF：治疗后，试验组（53.13±5.29）mm、（46.73±6.05）%，对照组（57.04±4.26）mm、（41.38±5.76）%，差异显著（P＜0.05）。不良反应：试验组2.44%，对照组7.32%，P＜0.05。总有效率：试验组95.12%，对照组78.05%，P＜0.05。sf-36评分：试验组（89.14±3.76）分，对照组（83.56±4.05）分，差异显著（P＜0.05）。结论：心力衰竭病人联用常规抗心衰药物和β-受体阻滞剂，其心功能与疗效及预后均得到显著改善，且药物副作用也较轻。
Keywords
心力衰竭；抗心衰药物；不良反应；β-受体阻滞剂
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 王鹏.常规抗心衰药物联合β-受体阻滞剂治疗心力衰竭[J].养生保健指南,2023,21(11):115-117.
[2] 宋薇.β-受体阻滞剂联合常规抗心衰药物治疗充血性心力衰竭的价值分析[J].保健文汇,2023,24(8):77-80.
[3] 郭亭亭.β-受体阻滞剂通过线粒体氧化应激途径减轻老年重度心力衰竭患者心肌缺血再灌注损伤[J].罕少疾病杂志,2023,30(2):33-35.
[4] 戴显鹏.β-受体阻滞剂在充血性心力衰竭治疗中的作用[J].中国现代药物应用,2023,17(4):107-109.
[5] PAOLA PATRICIA ARIZA-COLPAS, MARLON ALBERTO PINERES-MELO, ERNESTO BARCELO-MARTINEZ, et al. Heart Failure Mortality Prediction: A Comparative Study of Predictive Modeling Approaches[C]//Advances in Swarm Intelligence: 15th International Conference on Swarm Intelligence, ICSI 2024, Xining, China, August 23-26, 2024, Proceedings, Part II. 2024,13(24):403-416.
[6] 王会珍,葛廷,李红义.小剂量β-受体阻滞剂联合ACEI对经皮冠状动脉介入术后心力衰竭的疗效[J].深圳中西医结合杂志,2023,33(10):74-76.
[7] SHALEKA AGRAWAL, JOSEPH ASHBY, JEIYUN BAI, et al. Inherent Atrial Fibrillation Vulnerability in the Appendages Exacerbated in Heart Failure[C]//Statistical Atlases and Computational Models of the Heart. Regular and CMRxRecon Challenge Papers: 14th International Workshop, STACOM 2023, Held in Conjunction with MICCAI 2023, Vancouver, BC, Canada, October 12, 2023, Revised Selected Papers. 2024,17(2):220-229.
[8] 林柏青,刘军芬,刘洪清,等.达格列净联合β受体阻滞剂治疗EF<40%的心力衰竭合并室性心律失常的临床疗效观察[J].中国现代药物应用,2024,18(17):98-101.
[9] 卞小燕,张燕林.沙库巴曲缬沙坦钠与缬沙坦联合β受体阻滞剂在维持性血液透析合并心力衰竭患者中的应用效果比较[J].临床合理用药,2024,17(13):1-4.
[2] 宋薇.β-受体阻滞剂联合常规抗心衰药物治疗充血性心力衰竭的价值分析[J].保健文汇,2023,24(8):77-80.
[3] 郭亭亭.β-受体阻滞剂通过线粒体氧化应激途径减轻老年重度心力衰竭患者心肌缺血再灌注损伤[J].罕少疾病杂志,2023,30(2):33-35.
[4] 戴显鹏.β-受体阻滞剂在充血性心力衰竭治疗中的作用[J].中国现代药物应用,2023,17(4):107-109.
[5] PAOLA PATRICIA ARIZA-COLPAS, MARLON ALBERTO PINERES-MELO, ERNESTO BARCELO-MARTINEZ, et al. Heart Failure Mortality Prediction: A Comparative Study of Predictive Modeling Approaches[C]//Advances in Swarm Intelligence: 15th International Conference on Swarm Intelligence, ICSI 2024, Xining, China, August 23-26, 2024, Proceedings, Part II. 2024,13(24):403-416.
[6] 王会珍,葛廷,李红义.小剂量β-受体阻滞剂联合ACEI对经皮冠状动脉介入术后心力衰竭的疗效[J].深圳中西医结合杂志,2023,33(10):74-76.
[7] SHALEKA AGRAWAL, JOSEPH ASHBY, JEIYUN BAI, et al. Inherent Atrial Fibrillation Vulnerability in the Appendages Exacerbated in Heart Failure[C]//Statistical Atlases and Computational Models of the Heart. Regular and CMRxRecon Challenge Papers: 14th International Workshop, STACOM 2023, Held in Conjunction with MICCAI 2023, Vancouver, BC, Canada, October 12, 2023, Revised Selected Papers. 2024,17(2):220-229.
[8] 林柏青,刘军芬,刘洪清,等.达格列净联合β受体阻滞剂治疗EF<40%的心力衰竭合并室性心律失常的临床疗效观察[J].中国现代药物应用,2024,18(17):98-101.
[9] 卞小燕,张燕林.沙库巴曲缬沙坦钠与缬沙坦联合β受体阻滞剂在维持性血液透析合并心力衰竭患者中的应用效果比较[J].临床合理用药,2024,17(13):1-4.
Copyright © 2025 包月
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License